3 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)Digestive System Diseases, Dyslipidemias, Fibrosis, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, endocrine system disorder, fatty liver disease, hyperlipidemia, hyperthyroxinemia, liver disorder, metabolic disease, metabolic dysfunction-associated steatotic liver disease, thyroid gland disorder, thyroid hormone resistance syndromeActive, not recruitingPhase 32026-05-27NCT04951219
Understanding, Diagnosis and Monitoring of Thyroid Hormone Action Defectsendocrine system disorder, generalized resistance to thyroid hormone, hyperthyroxinemia, thyroid gland disorder, thyroid hormone resistance syndromeRecruitingNot stated2025-09-02NCT06307990
Register for Patients With Thyroid Hormone Resistance.Allan-Herndon-Dudley syndrome, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Craniofacial Abnormalities, Dyskinesias, Malformations of Cortical Development, Group I, Muscle Hypotonia, Musculoskeletal Abnormalities, Neurobehavioral Manifestations, Neurologic Manifestations, Neuromuscular Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, central nervous system malformation, cerebral cortical dysplasia, communication disorder, dystonic disorder, endocrine system disorder, hyperthyroxinemia, hypothyroidism, intellectual disability, learning disability, microcephaly, musculoskeletal system disorder, nervous system disorder, neurodevelopmental disorder, psychiatric disorder, thyroid gland disorder, thyroid hormone resistance syndrome, visual epilepsyRecruitingNot stated2024-08-22NCT06566066